No, 137 mg is NOT an appropriate testosterone pellet dose for women
Use of any testosterone preparation that results in supraphysiologic concentrations of testosterone, including pellets, is explicitly not recommended for women 1. A 137 mg pellet dose significantly exceeds evidence-based dosing parameters and violates current guideline recommendations.
Why This Dose is Problematic
The 2019 Global Consensus Position Statement—the highest-level guideline evidence available—clearly states that testosterone preparations resulting in supraphysiologic concentrations, specifically including pellets and injections, should not be used in women 1. This recommendation exists because:
- Pellets produce supraphysiologic peaks: Even lower doses (75-100 mg) produce testosterone levels exceeding 100-250 ng/dL in early phases, well above the physiologic premenopausal range 2
- 137 mg would amplify this problem: Recent pharmacokinetic data shows 100 mg pellets already cause statistically significant testosterone elevation 3, making 137 mg even more excessive
- Dosing variability is uncontrolled: Pellets demonstrate wide interindividual variability with no ability to titrate once implanted 2
What the Guidelines Actually Recommend
The evidence-based approach for women requires:
Transdermal formulations only: Non-oral routes (patches, creams, gels) are preferred because they maintain physiologic levels and have neutral lipid profiles 4, 5
Target physiologic premenopausal range: Testosterone concentrations must remain within 15-70 ng/dL (typical premenopausal range), not the supraphysiologic levels pellets produce 1, 5
Approved indication: Only for postmenopausal women with hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment 1
Monitoring protocol: Baseline total testosterone, repeat at 3-6 weeks, then every 6 months to screen for overuse and androgen excess 1
Critical Safety Concerns with Pellets
The FDA labeling for testosterone products warns about serious complications including venous thromboembolic events, cardiovascular risks, and abuse potential 6. While these labels address male formulations, the principle applies: supraphysiologic dosing increases risk.
Recent observational data on pellets shows:
- Minimal side effects reported in practice-based registries 3, 7
- BUT these studies lack adequate power, blinding, and confounder adjustment 2
- Safety signals for cardiovascular and metabolic outcomes remain sparse and inconsistent 2
- Long-term safety has not been established 5
What to Do Instead
If treating HSDD in a postmenopausal woman:
- Use off-label male transdermal formulations (gel, cream) at doses achieving physiologic female concentrations
- Start low: typical dosing approximates 3-5 mg daily transdermally
- Measure baseline total testosterone before starting
- Recheck at 3-6 weeks to ensure levels remain in physiologic range (15-70 ng/dL)
- Monitor every 6 months for clinical response and androgen excess signs
- Discontinue if no benefit by 6 months 1
Avoid compounded products unless no approved alternative exists, and only from pharmacies meeting Good Manufacturing Practice standards 1.
Common Pitfall
Practitioners may be tempted by pellet convenience (4-6 month duration) and patient preference, but convenience does not justify supraphysiologic dosing. The inability to remove or adjust pellets once implanted creates unacceptable risk when levels exceed physiologic range.
The evidence is unequivocal: pellets at any dose—especially 137 mg—contradict guideline recommendations prioritizing physiologic testosterone replacement 1, 5.